Atomoxetine Application Scope

Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years and older, adolescents, and adults. It helps improve attention, control impulsivity, and reduce hyperactive behavior by selectively inhibiting the reuptake of norepinephrine in the central nervous system.

Atomoxetine Characteristics

Ingredients:
- Atomoxetine Hydrochloride (400 mg/100 mL per bottle)
- Excipients: Purified Water, Flavors, Sweeteners, Stabilizers
Properties: Clear or slightly yellowish oral solution
Packaging Specification: 400 mg/100 mL per bottle, 1 bottle per box
Storage: Store below 25 °C, protected from light, keep tightly closed
Expiry Date: 24 months from date of manufacture
Executive Standard: In line with Chinese Pharmacopoeia standards
Approval Number: National Drug Approval No. H20090020 (China)
Date of Revision: December 2023
Manufacturer: Jianmin Pharmaceutical Group Co., Ltd.

Guidelines for the Use of Jianmin

Dosage and Administration:
- Recommended Dose:
  - Children and Adolescents (≤70 kg): Initial 0.5 mg/kg/day, may increase to 1.2 mg/kg/day after ≥3 days
  - Children and Adolescents (>70 kg) & Adults: Initial 40 mg/day, may increase to 80 mg/day after ≥3 days; maximum 100 mg/day
- Administration: Administer orally, once or twice daily, with or without food
- Missed Dose: Take as soon as remembered; skip if near next dose, do not double
Adverse Reactions:
- Common Adverse Reactions:
  - Decreased appetite
  - nausea
  - vomiting
  - dry mouth
  - fatigue
  - insomnia
  - dizziness
- Serious Adverse Reactions:
  - Rare cases of liver injury
  - suicidal ideation
  - severe allergic reaction
Contraindications:
- Known hypersensitivity to Atomoxetine or excipients
- Use within 14 days after MAO inhibitors
- Narrow-angle glaucoma
Precautions:
- Monitor growth in children
- Use with caution in cardiovascular disorders, hepatic impairment, and psychiatric disorders
- Monitor for suicidal thoughts, especially at treatment initiation

Atomoxetine Interactions

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may increase plasma concentration
Monitor when co-administered with pressor agents (e.g., pseudoephedrine)
Avoid use with MAO inhibitors

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.